Ostomy Care
Urology & Continence Care
Wound & Skin Care

Announcement no. 6/2013
13 August 2013

Q3 2012/13

Interim financial report, 9M 2012/13

(1 October 2012 - 30 June 2013)

Highlights

- Organic revenue growth was 6%. Revenue in DKK was up by 6% to DKK 8,665m.
- Organic growth rates by business area: Ostomy Care 7%, Continence Care 6%, Urology Care 9% and Wound & Skin Care 4%.
- Gross profit was up by 7% to DKK 5,837m, and the gross margin improved to 67% from 66% in the same period of last year.
- EBIT was up by 14% to DKK 2,699m. The EBIT margin was 31% against 29% in 9M 2011/12. At constant exchange rates, the EBIT margin was also 31%.
- The net profit for the reporting period was up by 24% to DKK 1,962m, and earnings per share improved by 23% relative to last year to DKK 9.14.
- The free cash flow amounted to DKK 1,650m, a DKK 183m increase on the same period of last year.
- ROIC after tax was 42%, compared with 36% in 9M 2011/12.

Financial guidance for 2012/13

- We continue to expect organic revenue growth of 6–7% and of 5–6% in DKK
- The EBIT margin is still forecast at 31–32%, both at constant exchange rates and in DKK.
- Capital expenditure is still expected to be around DKK 400m.
- The effective tax rate forecast is now expected to be about 25%.

Conference call
Coloplast will host a conference call on 13 August 2013 at 15.00 CEST. The call is expected to last about one hour. To attend the conference call, call +45 3271 4607, +44 (0)20 7162 0077 or +1 334 323 6201. A webcast will be posted on www.coloplast.com shortly after the conclusion of the conference call.

Coloplast

Financial highlights and key ratios

1 October - 30 June

	Consolidated		Change	Consolidated		Change
	DKK million			DKK million		
	2012/13	2011/12		2012/13	2011/12	
	9 mths	9 mths		Q3	Q3	
Income statement						
Revenue	8,665	8,174	6%	2,958	2,828	5%
Research and development costs	-286	-257	11%	-91	-80	14%
Operating profit before interest, tax, depreciation and amortisation (EBITDA)	3,070	2,740	12%	1,058	1,025	3%
Operating profit (EBIT)	2,699	2,364	14%	943	901	5%
Net financial income and expenses	-81	-226	-64%	-13	-103	-87%
Profit before tax	2,617	2,138	22%	930	798	17%
Profit for the period	1,962	1,586	24%	710	588	21%
Revenue growth						
Period growth in revenue, %	6	8		5	9	
Growth break down:						
Organic growth, %	6	6		7	5	
Currency effect, %	0	2		-2	4	
Balance sheet						
Total assets	8,637	9,980	-13%	8,637	9,980	-13%
Invested capital	6,660	6,552	2%	6,660	6,552	2%
Net interest-bearing debt	-791	-142	>100%	-791	-142	>100%
Equity end of period	6,155	5,372	15%	6,155	5,372	15%
Cash flow and investments						
Cash flow from operating activities	1,947	1,684	16%	888	883	1%
Cash flow from investing activities	-297	-217	37%	-110	-84	31%
Investments in property, plant and equipment, gross	-271	-225	20%	-101	-88	15%
Free cash flow	1,650	1,467	12%	778	799	-3%
Cash flow from financing activities	-3,022	-937	>100%	-1,586	-429	>100%
Key figures ratios						
Operating margin, EBIT, %	31	29		32	32	
Operating margin, EBITDA, %	35	34		36	36	
Return on average invested capital before tax (ROIC), %	55	49		57	55	
Return on average invested capital after tax (ROIC), %	42	36		43	40	
Return on equity, %	43	43		46	49	
Ratio of net debt to EBITDA	0	0		0	0	
Interest cover	52	70		151	85	
Equity ratio, %	71	54		71	54	
Rate of debt to enterprise value, %	-1	0		-1	0	
Net asset value per share, DKK[1)]	28	24	17%	28	24	17%
Per share data						
Share price, DKK[1)]	321	211	52%	321	211	52%
Share price/net asset value per share[1)]	12.0	8.8	36%	12.0	8.8	36%
Average number of outstanding shares, millions[1)]	210.7	210.0	0%	210.9	210.0	0%
PE, price/earnings ratio	25.9	21.0	23%	23.8	18.8	27%
Earnings per share (EPS), diluted[1)]	9.14	7.44	23%	3.30	2.76	20%
Free cash flow per share[1)]	7.8	7.0	12%	3.7	3.8	-3%

1) Comparative figures have been restated to reflect a 1-to-5 split of the company's A and B shares.

Management's report

Sales performance

Revenue in DKK was up by 6% to DKK 8,665m. The 9M organic growth rate was also 6%, while the Q3 organic growth rate was 7%.

Sales performance by business area

	DKK million		Growth composition			DKK million	Organic growth
	2012/13 9 mths	2011/12 9 mths	Organic growth	Exchange rates	Reported growth	2012/13 Q3	Q3
Ostomy Care	3,613	3,416	7%	-1%	6%	1,228	8%
Continence Care	3,029	2,852	6%	0%	6%	1,039	5%
Urology Care	844	771	9%	0%	10%	288	10%
Wound & Skin Care	1,179	1,135	4%	0%	4%	403	5%
Net revenue	**8,665**	**8,174**	**6%**	**0%**	**6%**	**2,958**	**7%**

Ostomy Care

Sales of ostomy care products in the 9M period amounted to DKK 3,613m, which translated into reported growth of 6%. Organic growth, at 7%, was driven by the portfolio of SenSura® products and the Brava™ series of accessories in Europe and the USA and by Assura® ostomy care products in emerging markets such as China and Brazil.

The Q3 organic growth of 8% was driven by sustained satisfactory growth in Europe and by increased growth rates in the USA, Brazil and China relative to the first six months of the financial year.

Continence Care

Continence Care revenue was DKK 3,029m, a 6% improvement, both in DKK and organically. Sales of SpeediCath® intermittent catheters, especially of compact catheters, were highly satisfactory, whereas sales of SelfCath® and EasiCath® catheters declined slightly, especially due to the highly competitive US market.
Urine bag and uridome sales increased slightly in the 9M period, especially due to continuing price pressure on urine bags in the main European markets. Sales of the Peristeen® anal irrigation system continued to contribute to growth, although the growth rate has declined over the past 12 months.

Organic growth in the third quarter was 5%, impacted in particular by the UK market which produced negative growth in the period due to the consolidation in the number of UK distributors in Q3 2011/12, which led to stockbuilding. Apart from this factor, the growth performance was satisfactory.

Urology Care

Sales of urology care products improved by 10% in the 9M 2012/13 period to DKK 844m at 9% organic growth. Growth was driven by Titan® penile implants, which continue to win market share in the USA.
Sales of Restorelle® for pelvic organ prolapse repair increased in a contracting market, and sales of slings for treating female stress incontinence were satisfactory, albeit declining. Sales of disposable surgical products, in particular of endourological products, were also satisfactory.

Q3 organic growth was 10%. The growth performance was satisfactory in all product areas. The highly satisfactory roll-out of Altis®, the single incision sling, continues.

Wound & Skin Care

Sales of wound and skin care products amounted to DKK 1,179m, equal to a 4% increase in the 9M period, both in DKK and organically. Wound Care sales improved by 2% in the 9M period. Sales of

Biatain® foam dressings, especially foam dressings with a silicone adhesive, were the main growth driver. Sales of Comfeel® hydrocolloid dressings continued to decline due to a change in user preferences in Europe, and the drop was only partly offset by growth in emerging markets. Overall sales in Europe also declined, but the effect was more than offset by growth in emerging markets and in the USA.

The Q3 organic growth rate was 5% with the Wound Care business also reporting 5% growth. The positive performance of the Wound Care business was attributable to high growth rates in China, Greece, the USA and Brazil, which more than offset the persistently negative growth in Europe. However, the growth rate in Europe improved relative to the first six months of the year. The North American Skin Care business and the contract production of Compeed® once again reported satisfactory growth rates, albeit at lower levels than in the two preceding quarters.

Spain and the Netherlands continued to suffer negative growth in challenging local market environments.

Q3 organic growth was 4%. The sales growth of ostomy care products was in line with the H1 2012/13 growth rate, whereas continence care products were well below the H1 2012/13 growth rate due to the aforementioned stockbuilding in Q3 last year. Urology Care contributed nicely to the Q3 growth performance, whereas Wound Care continued to lose sales although by less than in the H1 2012/13 period.

Other established markets

Revenue was up by 7% to DKK 1,782m. Organic growth was 8%, driven by satisfactory growth in the USA. Sales growth in the US Ostomy Care business was substantially higher than last year, especially due to highly satisfactory sales of the Brava™ series of accessories, whereas growth rates in Continence Care continued to decline. Wound and Skin Care sales were highly satisfac

Sales performance by region

	DKK million		Growth composition			DKK million	Organic growth
	2012/13 9 mths	2011/12 9 mths	Organic growth	Exchange rates	Reported growth	2012/13 Q3	Q3
European markets	5,784	5,536	4%	0%	4%	1,992	4%
Other developed markets	1,782	1,667	8%	-1%	7%	594	10%
Emerging markets	1,099	971	15%	-2%	13%	372	17%
Net revenue	**8,665**	**8,174**	**6%**	**0%**	**6%**	**2,958**	**7%**

European markets

Revenue amounted to DKK 5,784m, which translated into reported growth of 4%. Organic growth in the European business was also 4%. Most of the major markets reported satisfactory sales of ostomy care products. The Continence Care business reported a lower growth rate than in the first six months of the year, due to stockbuilding by UK distributors in Q3 2011/12. A positive performance is expected in Q4 2012/13, because inventories fell in the UK in Q4 2011/12. The Wound Care business remained a negative contributor to growth.

tory. Growth in sales of penile implants and synthetic
mesh products for pelvic organ prolapse also contributed to the region's overall growth performance.

Q3 organic growth was 10%. The increase relative to the H1 growth rate was driven by higher growth rates in the US Ostomy Care and Continence Care businesses, as especially the Continence Care business was impacted by inventory reductions in the second quarter caused by consolidation among distributors. In other markets, growth in ostomy care products recovered as expected in Japan, and both Canada and Australia reported an increase in sales growth relative to H1 2012/13.

Other markets

Revenue increased by 13% to DKK 1,099m, while organic growth was 15%. Growth in the 9M period was driven by China, Greece, Brazil and Argentina. Sales in the Russian market were in line with the same period of last year. In addition to a very strong performance in Q1 2011/12, the lack of growth in Russia was due to a number of large tenders being postponed or cancelled.

The Q3 growth rate was 17%. Growth rates for both Ostomy Care and Wound Care improved in China, and Brazil reported a highly satisfactory third quarter performance, which was partly due to last year's weak third quarter. Greece also reported highly satisfactory sales growth, especially in the Wound Care business.

Gross profit

Gross profit for the 9M period was up by 7% to DKK 5,837m from DKK 5,433m in the same period of last year. The gross margin was 67%, against 66% in 9M 2011/12. The change was the result of improvements in production efficiency and higher revenue. At constant exchange rates, the gross margin was also 67%.

The Q3 gross margin was 68%, both at constant exchange rates and in DKK.

Capacity costs

Distribution costs amounted to DKK 2,463m in the 9M period and accounted for 28% of revenue. When adjusted for non-recurring items, distribution costs as a percentage of revenue were in line with last year’s figure.

The Q3 distribution costs accounted for 29% of revenue, the higher percentage being due to increased investments in sales-enhancing activities.

Administrative expenses amounted to DKK 411m, against DKK 484m in 9M 2011/12. Administrative expenses accounted for 5% of revenue, which was in line with the same period of last year when adjusted for last year's DKK 66m provision for losses on trade receivables in southern Europe.

The Q3 administrative expenses also accounted for 5% of revenue. Provisions for losses on trade receivables in southern Europe were reduced by DKK 10m during the quarter.

R&D costs were DKK 286m in the 9M period and accounted for 3% of revenue, which was in line with the same period of last year.

The Q3 R&D costs also accounted for 3% of revenue.

Other operating income and other operating expenses amounted to a net income of DKK 22m, against a net income of DKK 5m in 9M 2011/12.

Operating profit (EBIT)

EBIT was DKK 2,699m, a 14% increase from DKK 2,364m in 9M 2011/12. The EBIT margin was 31% both at constant exchange rates and in DKK, against 29% in the same period of last year. Adjusted for non-recurring costs totalling DKK 65m and a total of DKK 66m in provisions for losses on trade receivables in southern Europe, last year's 9M EBIT margin was also 31%.

The Q3 EBIT margin was 32%. The improvement relative to the first two quarters of the year were driven mainly by the higher absolute revenue in the third quarter.

Financial items

	DKK million		DKK million	
	2012/13	2011/12	2012/13	2011/12
	9 mths	9 mths	Q3	Q3
Interest, net	-29	-39	-5	-12
Fair value adjustment of options	-19	-27	-1	-8
Net exchange adjustments	-12	-144	3	-80
Other financial items	-21	-16	-10	-3
Total financial items	**-81**	**-226**	**-13**	**-103**

Financial items and tax

Financial items amounted to a net expense of DKK 81m, against a net expense of DKK 226m in the same period of last year, the difference being mainly due to a relatively large realised net loss on forward currency contracts last year and a net gain in the current year.

The effective tax rate was 25%, one percentage point less than last year, for a tax expense of DKK 655m, as compared with DKK 552m in 9M 2011/12.

The effective tax rate for the third quarter was 23%. This year's lower Q3 tax expense was due to a DKK 35m adjustment of deferred tax balances as a result of the reduction of the Danish corporate tax rate taking effect from 2014 onwards.

Net profit for the period

The net profit for the reporting period was up by 24% to DKK 1,962m relative to 9M 2011/12, while earnings per share improved by 23% relative to 9M 2011/12 to DKK 9.14.

Cash flows and investments

Cash flows from operating activities

Cash flows from operating activities were up by 16% to DKK 1,947m from DKK 1,684m in 9M 2011/12.

Most of the improvement was due to a DKK 330m EBITDA increase and a combined DKK 310m year-on-year drop in realised net losses on forward currency contracts and other foreign exchange adjustments. Increases in income tax paid and in working capital reduced the cash flows for the period by DKK 231m and DKK 156m respectively.

Investments (CAPEX)

Coloplast made gross investments of DKK 297m in 9M 2012/13 compared with DKK 217m in 9M 2011/12. The increase was due to a larger amount invested in machinery to be used for new products. Gross investments in property, plant and equipment and in intangible assets (CAPEX) amounted to DKK 295m, against DKK 236m in 9M 2011/12, corresponding to 3% of revenue both this year and last year.

Free cash flow

The free cash flow amounted to DKK 1,650m against DKK 1,467m in the same period of last year.

The Q3 free cash flow amounted to DKK 778m against DKK 799m in the same period of last year. Last year's cash flows included a large payment of overdue receivables in Spain, which reduced the working capital substantially.

Capital reserves

The confirmed credit facilities expired in the third quarter of 2012/13 and are thus not included in long-term capital reserves. Instead of confirmed facilities, Coloplast will maintain cash reserves of around DKK 1 billion. At the balance sheet date, the gross interest-bearing debt amounted to DKK 161m. Coloplast repaid most of its outstanding debt in April 2013.

Balance sheet and equity

Balance sheet

At DKK 8,637m, total assets were DKK 1,539m lower than at 30 September 2012.

Intangible assets amounted to DKK 1,584m, which was DKK 121m less than at 30 September 2012. The reduction was mainly due to the amortisation of acquired patents and trademarks as well as the depreciation of USD against DKK since the beginning of the financial year.

Current assets fell by DKK 1,418m relative to 30 September 2012 to stand at DKK 4,551m. The reduction was due to the repayment of loans, distribution of extraordinary dividends and share buybacks.

Relative to 30 September 2012, trade receivables were up by 5% to DKK 2,027m and inventories were up by DKK 79m to DKK 1,087m. Trade payables were reduced by DKK 45m relative to 30 September 2012 to DKK 433m.
Working capital made up 23% of revenue, which was 1 percentage point higher than at 30 September 2012.

Equity

Equity increased by DKK 113m during the reporting period to DKK 6,155m. The comprehensive income for the period of DKK 2,003m was partly offset by dividend payments of DKK 1,476m. The net effect of treasury shares acquired, employees' exercise of share options and the sale of employee shares reduced equity by DKK 414m.

Share buy-backs

At the general meeting held on 11 December 2012, the shareholders authorised Coloplast to establish a share buy-back programme totalling up to DKK 1bn until the end of the 2012/13 financial year. The second half of the programme, for DKK 500m, was launched in February 2013 (see Announcement No. 4/2013) and it closed in July 2013. At 30 June 2013, Coloplast had bought back shares for a total of DKK 416m.

Treasury shares

At 30 June 2013, Coloplast's holding of treasury shares consisted of 9,436,624 B shares, which was 5,310,836 fewer than at 30 September 2012. The holding was reduced due to the cancellation of 5 million shares.

Financial guidance for 2012/13

- We continue to expect organic revenue growth of 6–7% and of 5–6% in DKK
- The EBIT margin is still forecast at 31–32%, both at constant exchange rates and in DKK.
- Capital expenditure is still expected to be around DKK 400m.
- The effective tax rate forecast is now expected to be about 25%.

The financial guidance assumes sustained stable growth in the European business. In addition, emerging markets are expected to grow by at least the same rates as last year, while the mature markets outside Europe, especially the USA, are expected to see higher growth rates than in 2011/12.
Price pressures in 2012/13 are expected to be in line with those of 2011/12. Our financial guidance takes account of reforms with known effects.

The EBIT margin guidance assumes that Coloplast, in addition to delivering on the sales growth, can successfully deliver results consistent with the previously estimated productivity-enhancement potential of a 0.5–1.0% overall improvement of the gross margin.

The guidance also includes expected investments in sales-enhancing initiatives under the revised strategy.

Coloplast's current long-term financial ambition is to outgrow the market while achieving earnings margins that are in line with the best performing med-tech companies[1].
The overall weighted market growth in Coloplast's current markets is expected to be 4–5% and was last revised at the release of the full-year financial results for 2011/12.

[1] Coloplast's current peer group consists of the following listed med-tech companies: Medtronic Inc., Baxter International Inc., Covidien PLC, Stryker Corp., St. Jude Medical Inc., Boston Scientific Corp., Sonova Holding AG, Smith&Nephew PLC, CR Bard Inc., Getinge AB, WDH A/S, Shandon Weigao Group Medical.

Other matters

Update on mesh litigation

Since 2011, Coloplast has been named as a defendant in individual lawsuits in various federal and state courts around the United States, alleging injury resulting from use of transvaginal surgical mesh products designed to treat pelvic organ prolapse and stress incontinence.
On August 6, 2012, a multidistrict litigation (MDL) was formed to consolidate federal court cases in which Coloplast is the first named defendant in the Southern District of West Virginia as part of MDL No. 2387. The cases are consolidated for purposes of pre-trial discovery and motion practice only. Separate MDLs have also been formed to manage litigation against other major mesh manufacturers in the same venue. A date has not yet been set for the hearing of cases against Coloplast. Coloplast cannot predict the timing or outcome of any such litigation, or whether any additional litigation will be brought against the company or its subsidiaries. Based on the current information available to Coloplast, we do not expect this to have a significant financial impact on the company.

Expanding production capacity in Hungary

We have decided to expand the production capacity at the Coloplast factory in Nyírbátor, Hungary. The total investment will amount to DKK 130–150m.

France announces reduction of reimbursement rates

In July 2013, Coloplast was notified by the French healthcare authorities of a reduction in reimbursement rates for ostomy care and continence care products. Effective from 1 September 2013, rates are expected to be lowered by 5%, of which Coloplast is expected to absorb 3.2 percentage points of the reduction. The full-year effect on both revenue and EBIT is estimated at DKK 30–40m.

Change in French reimbursement rules for wound care products containing silver

Effective from 27 May 2013, wound care dressings containing silver and ibuprofen have no longer qualified for reimbursement. The change does not apply to products sold to hospitals. The full-year revenue effect is estimated at DKK 10-15m, most of which will also feed through to EBIT.

Reduction of Danish corporate tax rate

The Danish parliament has voted to lower the corporate tax rate from the current rate of 25% to 22% in 2016. The rate will be lowered by 0.5 point in 2014, by 1 point in 2015 and by 1.5 point in 2016.

Exchange rate exposure

Our financial guidance for the 2012/13 financial year has been prepared on the basis of the following assumptions for the company's main currencies:

DKK	*GBP*	*USD*	*HUF*	*EUR*
Average exchange rate 2011/12*	904	574	2,53	744
Spot rate, 7 August 2013	859	561	2,49	746
Estimated average exchange rate 2012/2013	884	568	2,54	746
Change in estimated average exchange rates compared with last year**	-2%	-1%	0%	0%

*) Average exchange rates from 1 October 2011 to 30 September 2012.

**) Estimated average exchange rate is calculated as the average exhange rate year to date combined with the spot rate for 7 August 2013.

Revenue is particularly exposed to developments in USD and GBP relative to DKK. Fluctuations in HUF against DKK have an effect on the operating profit, because a substantial part of our production, and thus of our costs, are in Hungary, whereas our sales there are moderate.

In DKK millions over 12 months on a 10% initial drop in DKK exchange rates (Average exchange rates 2011/12)	Revenue	EBIT
USD	-160	-45
GBP	-180	-105
HUF	0	35

Forward-looking statements

The forward-looking statements in this announcement, including revenue and earnings guidance, do not constitute a guarantee of future results and are subject to risk, uncertainty and assumptions, the consequences of which are difficult to predict. The forward-looking statements are based on our current expectations, estimates and assumptions and are provided on the basis of information available to us at the present time. Major fluctuations in the exchange rates of key currencies, significant changes in the healthcare sector or major developments in the global economy may impact our ability to achieve the defined long-term targets and meet our guidance. This may impact our company's financial results.

Statement by the Board of Directors and the Executive Management

The Board of Directors and the Executive Management today considered and approved the interim report of Coloplast A/S for the period 1 October 2012 – 30 June 2013. The interim report, which is unaudited, is presented in accordance with IAS 34 "Interim financial reporting" as adopted by the EU and additional Danish disclosure requirements for interim reports of listed companies.

In our opinion, the interim report gives a true and fair view of the Group's assets, equity, liabilities and financial position at 30 June 2013 and of the results of the Group's operations and cash flows for the period 1 October 2012 – 30 June 2013.

Also, in our opinion, the management's report includes a fair account of the development and performance of the Group, the results for the period and of the financial position of the Group, together with a description of the principal risks and uncertainties that the Group faces.

Humlebæk, 13 August 2013

Executive Management:

Lars Rasmussen President, CEO	Lene Skole Executive Vice President, CFO

Board of Directors:

Michael Pram Rasmussen Chairman	Niels Peter Louis-Hansen Deputy Chairman	Per Magid
Brian Petersen	Jørgen Tang-Jensen	Sven Håkan Björklund
Thomas Barfod Elected by the employees	Jane Lichtenberg Elected by the employees	Torben Rasmussen Elected by the employees

Tabeller

Unaudited

Statement of comprehensive income

1 October - 30 June

(Unaudited)

Note		Consolidated DKK million 2012/13 9 mths	2011/12 9 mths	Index	Consolidated DKK million 2012/13 Q3	2011/12 Q3	Index
1	Revenue	8,665	8,174	106	2,958	2,828	105
	Cost of sales	-2,828	-2,741	103	-945	-908	104
	Gross profit	**5,837**	**5,433**	**107**	**2,013**	**1,920**	**105**
	Distribution costs	-2,463	-2,333	106	-849	-780	109
	Administrative expenses	-411	-484	85	-137	-163	84
	Research and development costs	-286	-257	111	-91	-80	114
	Other operating income	30	26	115	10	7	143
	Other operating expenses	-8	-21	38	-3	-3	100
1	**Operating profit (EBIT)**	**2,699**	**2,364**	**114**	**943**	**901**	**105**
	Profit/loss after tax on investment in associates	-1	0		0	0	
2	Financial income	33	47	70	17	17	100
3	Financial expenses	-114	-273	42	-30	-120	25
	Profit before tax	**2,617**	**2,138**	**122**	**930**	**798**	**117**
	Tax on profit for the period	-655	-552	119	-220	-210	105
	Net profit for the period	**1,962**	**1,586**	**124**	**710**	**588**	**121**
	Other comprehensive income						
	Items that will not be reclassified to profit or loss:						
	Actuarial gains/losses	-10	0		-3	0	
	Tax on actuarial gains/losses	2	0		0	0	
		-8	0		-3	0	
	Items that may be reclassified subsequently to profit or loss:						
	Value adjustment of currency and interest hedging	174	-148		84	-56	
	Of which transferred to financial items	-18	94		-16	44	
	Tax effect of hedging	-39	14		-17	3	
	Currency adjustment, assets in foreign currency	-10	83		-17	70	
	Currency adjustment of opening balances and other adjustments relating to subsidiaries	-58	68		38	52	
		49	111		72	113	
	Total other comprehensive income	**41**	**111**		**69**	**113**	
	Total comprehensive income	**2,003**	**1,697**		**779**	**701**	
	Earnings per Share (EPS)	9.31	7.56		3.37	2.80	
	Earnings per Share (EPS), diluted	9.14	7.44		3.30	2.76	
	Profit distribution:						
	Retained earnings	1,330	1,586				
	Paid interim dividend	632	0				
	Total	**1,962**	**1,586**				

Balance sheet

At 30 June

		Consolidated		
		DKK million		
Note		30.06.13	30.06.12	30.09.12
	Assets			
	Acquired patents and trademarks etc.	731	888	837
	Goodwill	757	783	767
	Software	68	84	79
	Prepayments and intangible assets in progress	28	17	22
	Intangible assets	**1,584**	**1,772**	**1,705**
	Land and buildings	1,018	1,116	1,107
	Plant and machinery	764	852	826
	Other fixtures and fittings, tools and equipment	121	124	121
	Prepayments and property, plant and equipment under construction	364	190	232
	Property, plant and equipment	**2,267**	**2,282**	**2,286**
	Investment in associates	14	6	7
	Deferred tax asset	205	183	193
	Other receivables	16	17	16
	Investments	**235**	**206**	**216**
	Non-current assets	**4,086**	**4,260**	**4,207**
	Inventories	**1,087**	**962**	**1,008**
	Trade receivables	2,027	1,895	1,922
	Income tax	56	12	55
	Other receivables	335	262	282
	Prepayments	94	67	84
	Receivables	**2,512**	**2,236**	**2,343**
	Marketable securities	**335**	**608**	**645**
	Cash and cash equivalents	**617**	**1,914**	**1,973**
	Current assets	**4,551**	**5,720**	**5,969**
	Assets	**8,637**	**9,980**	**10,176**

Balance sheet

At 30 June

Note		Consolidated DKK million		
		30.06.13	30.06.12	30.09.12
	Equity and liabilities			
	Share capital	220	225	225
	Reserve for currency and interest hedging	77	-72	-40
	Proposed dividend for the year	0	0	841
	Retained earnings	5,858	5,219	5,016
	Total equity	**6,155**	**5,372**	**6,042**
	Provisions for pensions and similar liabilities	163	119	157
	Provision for deferred tax	166	181	176
	Other provisions	7	5	5
	Mortgage debt	0	352	0
	Other credit institutions	0	440	0
	Other payables	16	18	16
	Deferred income	69	78	72
	Non-current liabilities	**421**	**1,193**	**426**
	Provisions for pensions and similar liabilities	12	6	13
	Other provisions	10	16	14
	Other credit institutions	146	1,343	1,296
	Trade payables	433	368	478
	Income tax	625	512	671
	Other payables	828	1,144	1,208
	Deferred income	7	26	28
	Current liabilities	**2,061**	**3,415**	**3,708**
	Current and non-current liabilities	**2,482**	**4,608**	**4,134**
	Equity and liabilities	**8,637**	**9,980**	**10,176**
7	Contingent liabilities			

Statement of changes in equity

Consolidated DKK million	Share capital A shares	Share capital B shares	Reserve for currency and interest rate hedging	Proposed dividend	Retained earnings	Total equity
2012/13						
Restated balance at 1.10.	18	207	-40	841	5,016	6,042
Comprehensive income:						
Net profit for the period				632	1,330	1,962
Other comprehensive income			117		-76	41
Total comprehensive income for the period	*0*	*0*	*117*	*632*	*1,254*	*2,003*
Transactions with shareholders:						
Transfers				3	-3	0
Investment in treasury shares					-579	-579
Sale of treasury shares					141	141
Share-based payment					24	24
Capital reduction		-5			5	0
Dividend paid out in respect of 2011/12				-1,476		-1,476
Total transactions with shareholders:	*0*	*-5*	*0*	*-1,473*	*-412*	*-1,890*
Balance at 30.06	**18**	**202**	**77**	**0**	**5,858**	**6,155**
2011/12						
Balance at 1.10 as per annual report	18	207	-32	585	3,674	4,452
Comprehensive income:						
Net profit for the period					1,586	1,586
Other comprehensive income			-40		151	111
Total comprehensive income for the period	*0*	*0*	*-40*	*0*	*1,737*	*1,697*
Transactions with shareholders:						
Transfers				2	-2	0
Investment in treasury shares					-500	-500
Sale of treasury shares					293	293
Share-based payment					21	21
Tax on equity entries					-4	-4
Dividend paid out in respect of 2010/11				-587		-587
Total transactions with shareholders:	*0*	*0*	*0*	*-585*	*-192*	*-777*
Restated balance at 30.06	**18**	**207**	**-72**	**0**	**5,219**	**5,372**

Cash flow statement

1 October - 30 June

		Consolidated	
		DKK million	
		2012/13	2011/12
Note		9 mths	9 mths
	Operating profit	2,699	2,364
	Depreciation, amortisation and impairment	371	376
4	Adjustment for other non-cash operating items	-3	-13
5	Changes in working capital	-352	-196
	Ingoing interest payments, etc.	15	47
	Outgoing interest payments, etc.	-12	-354
	Income tax paid	-771	-540
	Cash flows from operating activities	**1,947**	**1,684**
	Investments in intangible assets	-24	-11
	Investments in land and buildings	-4	-3
	Investments in plant and machinery	-52	-73
	Investments in property, plant and equipment under construction	-215	-149
	Property, plant and equipment sold	6	19
	Acquisition of associate	-8	0
	Cash flow from investing activities	**-297**	**-217**
	Free cash flow	**1,650**	**1,467**
	Dividend to shareholders	-1,476	-587
	Net investment in treasury shares and exercise of share options	-439	-206
	Financing from shareholders	**-1,915**	**-793**
	Acquisition of bonds	310	-40
	Financing through long-term borrowing, debt funding	0	0
	Financing through long-term borrowing, instalments	-1,417	-104
	Cash flows from financing activities	**-3,022**	**-937**
	Net cash flows for the period	**-1,372**	**530**
	Cash, cash equivalents and short-term debt at 1.10.	1,830	1,220
	Value adjustment of cash and bank balances	13	2
	Net cash flows for the period	-1,372	530
6	**Cash, cash equivalents and short-term debt at 30.06**	**471**	**1,752**

The cash flow statement cannot be derived using only the published financial data.

Notes

1. Segment information

Consolidated, 2012/13

Operating segments

The operating segments are defined on the basis of the monthly reporting to the Executive Management, which is considered the senior operational management. Reporting to Management is based on two global operating segments, Sales Regions and Production Units, as well as three smaller operating segments: Wound and Skin Care, Porgès and Surgical Urology (SU). The segments Global Marketing, Global R&D and Staff are not operating segments, as they do not aim to generate revenue. This breakdown also reflects our global organisational structure.

The operating segments Sales Regions and Production Units segments comprise sales and production from each of our three business areas, Ostomy Care, Urology Care, Continence Care and Wound and Skin Care. Inter-segment trading consists of the Sales Regions procuring goods from the Production Units. Trading takes place on an arm's length basis.

The operating segment Wound and Skin Care exclusively covers the sale of wound and skin care products in selected European markets, where the Wound and Skin Care segment is separate from the other business areas. The sale of wound and skin care products in other markets is included in the Wound and Skin Care business area of the Sales Regions operating segment. Porgès covers the production and sale of disposable urology products, while SU covers the sale of urology products. The segmentation reflects the structure of reporting to the Executive Management.

The Wound and Skin Care, Porgès and SU operating segments are included in the reporting segment Sales Regions as they meet the criteria for combination. Accordingly, the operating segments Wound and Skin Care, Porgès and SU are non-reporting segments. The shared/non-allocated segment comprises support functions (Global marketing, Global R&D and Staff) and eliminations, as these segments do not generate revenue. The segments listed (with the exception of SU) each represent less than 10% of total segment revenue, segment profit/loss and segment assets. The SU operating segment represents more than 10% of total assets, but as the assets are exclusively allocated to the segments in connection with impairment tests and are not reported by segment to Management, the segment is not considered a reporting segment. Financial items and income tax are not allocated to the operating segments.

Management reviews each operating segment separately based on EBIT and allocates resources on that background. The performance targets are calculated the same way as in the consolidated financial statements.
Costs are allocated directly to segments. Certain immaterial indirect costs are allocated systematically to the Shared/Non-allocated segment and the reporting segments Sales Regions and Production Units.

Management does not receive reporting on asset and liabilities by the reporting segments Sales Regions and Production Units. Accordingly, the reporting segments are not measured in this respect, nor do we allocate resources on this background. No single customer accounts for more than 10% of revenue.

Operating segments

	Sales regions[1)]		Production units[1)]		Shared/ Non-allocated		Total	
DKK million	2012/13	2011/12	2012/13	2011/12	2012/13	2011/12	2012/13	2011/12
External revenue	8,665	8,174	0	0	0	0	8,665	8,174
Segment operating profit (EBIT)	579	519	3,260	3,104	-1,140	-1,259	2,699	2,364
Net financials	0	0	0	0	-81	-226	-81	-226

[1)] Due to a change in segment reporting taking effect from the second quarter a part of the contract production will henceforth be reported under the sales regions. The changes exclusively reflect a reclassification from the reporting segment 'Production units' to the reporting segment 'Sales regions'. Due to the change, the external revenue between the segments has changed by DKK 164m (2011/12: DKK 153m) and EBIT has changed by DKK 63m (2011/12: DKK 52m).

Notes

	Consolidated DKK million	
	2012/13	2011/12
2. Financial income		
Interest income	15	45
Fair value adjustments on forward contracts transferred from equity	18	0
Other financial income and fees	0	2
Total	**33**	**47**
3. Financial expenses		
Interest expense	44	84
Fair value adjustments, share options	19	27
Fair value adjustments on forward contracts transferred from equity	0	94
Net exchange adjustments	30	50
Other financial expenses and fees	21	18
Total	**114**	**273**
4. Adjustment for other non-cash operating items		
Net gain/loss on divestment of non-current assets	0	3
Change in other provisions	-3	-16
Total	**-3**	**-13**
5. Changes in working capital		
Inventories	-135	18
Trade receivables	-169	-24
Other receivables	-70	-23
Trade and other payables etc.	22	-167
Total	**-352**	**-196**
6. Cash and short-term debt		
Cash	1	1
Bank balances	616	1,913
Cash and bank balances	**617**	**1,914**
Short-term debt	-146	-1,343
Of which bullet loans transferred during the year from non-current liabilities	0	1,181
Total	**471**	**1,752**

7. Contingent liabilities

In addition to a few minor legal proceedings, the Coloplast Group is a party to individual lawsuits in various federal and state courts around the United States, alleging injury resulting from use of transvaginal surgical mesh products designed to treat pelvic organ prolapse and stress urinary incontinence. Based on the current information available to Coloplast, we do not expect this to have a significant financial impact on the Group's financial position.

Income statement, quarterly

(Unaudited)

DKK million		Consolidated						
		2011/12				2012/13		
Note		Q1	Q2	Q3	Q4	Q1	Q2	Q3
1	Revenue	2,654	2,692	2,828	2,849	2,865	2,842	2,958
	Cost of sales	-916	-917	-908	-937	-935	-948	-945
	Gross profit	**1,738**	**1,775**	**1,920**	**1,912**	**1,930**	**1,894**	**2,013**
	Distribution costs	-782	-771	-780	-839	-812	-802	-849
	Administrative expenses	-163	-158	-163	-138	-137	-137	-137
	Research and development costs	-95	-82	-80	-85	-92	-103	-91
	Other operating income	8	11	7	42	10	10	10
	Other operating expenses	-13	-5	-3	-1	-2	-3	-3
1	**Operating profit (EBIT)**	**693**	**770**	**901**	**891**	**897**	**859**	**943**
	Profit/loss after tax on investment in associates	0	0	0	-1	0	-1	0
2	Financial income	16	14	17	-5	7	9	17
3	Financial expenses	-59	-94	-120	-69	-72	-12	-30
	Profit before tax	**650**	**690**	**798**	**816**	**832**	**855**	**930**
	Tax on profit for the period	-166	-176	-210	-208	-215	-220	-220
	Net profit for the period	**484**	**514**	**588**	**608**	**617**	**635**	**710**
	Earnings per Share (EPS)	2.32	2.43	2.79	2.89	2.93	3.01	3.37
	Earnings per Share (EPS), diluted	2.27	2.40	2.76	2.86	2.88	2.95	3.30

For further information, please contact

Investors and analysts

Lene Skole
Executive Vice President, CFO
Tel. +45 4911 1700

Ian S.E. Christensen
Vice President, Investor Relations
Tel. +45 4911 1800/+45 4911 1301
Email: dkisec@coloplast.com

Henrik Nord
Senior Manager, Investor Relations
Tel. +45 4911 1800/+45 4911 3108
Email: dkhno@coloplast.com

Press and the media

Ulla Lundhus
Head of Media and Positioning
Tel. +45 4911 1929
Email: dkul@coloplast.com

Website

www.coloplast.com

Address

Coloplast A/S
Holtedam 1
3050 Humlebæk
Denmark

CVR No. 69749917

This announcement is available in a Danish and an English-language version.
In the event of discrepancies, the Danish version shall prevail.

Coloplast develops products and services that make life easier for people with very personal and private medical conditions. Working closely with the people who use our products, we create solutions that are sensitive to their special needs. We call this intimate healthcare.

Our business includes Ostomy Care, Urology Care, Continence Care and Wound and Skin Care. We operate globally and employ around 8,000 people.